<p>在 1 月 15 日最近的 SEC 文件中，<strong>Astrana Health</strong>（纳斯达克： ASTH）的董事施密特进行了值得注意的交易，涉及行使公司股票期权。</p>
<p><strong>发生了什么：</strong> 周四，美国证券交易委员会的 Form 4 文件显示，<strong>Astrana Health</strong> 的董事施密特刚刚行使了价值 20,000 股 ASTH 股票的股票期权，行使价格为 5.79 美元。</p>
<p>在周五的早盘交易中，<strong>Astrana Health</strong> 的股价下跌了 0.0%，目前价格为 27.38 美元。考虑到当前价格，施密特的 20,000 股总价值为 431,800 美元。</p>
<h3>揭示 Astrana Health 背后的故事</h3>
<p>Astrana Health Inc 是一家以患者为中心、以医生为中心的综合性人口健康管理公司。该公司致力于以成本效益的方式提供协调的、基于结果的医疗服务。它专注于医生提供高质量的医疗服务、人口健康管理和患者护理协调，特别是针对老年患者和多种慢性病患者。公司的三个可报告部门是护理合作伙伴、护理交付和护理赋能。它的主要收入来自护理合作伙伴部门。</p>
<h3>关键指标：Astrana Health 的财务健康状况</h3>
<p><strong>收入增长：</strong> 在过去的三个月中，Astrana Health 表现积极，截至 2025 年 9 月 30 日，收入增长率达到了 <strong>99.71%</strong>。这反映了公司顶线收入的显著增长。与竞争对手相比，该公司的增长率超过了医疗保健行业的平均水平。</p>
<p><strong>盈利能力指标的关键见解：</strong></p>
<ul>
<li>毛利率：该公司发出成本效率警告，毛利率仅为 10.17%，表明与同行相比在维持盈利能力方面可能面临困难。</li>
</ul>
<ul>
<li>每股收益（EPS）：Astrana Health 的每股收益反映出下降，当前 EPS 为 0.01，低于行业平均水平。</li>
</ul>
<p><strong>债务管理：</strong> Astrana Health 的债务与股本比率为 <strong>1.4</strong>，低于行业平均水平，反映出对债务融资的依赖较低，财务策略更加保守。</p>
<p><strong>评估估值指标：</strong></p>
<ul>
<li>市盈率（P/E）比率：Astrana Health 当前的市盈率为 144.11，高于行业平均水平，表明根据市场情绪，该股票可能被高估。</li>
</ul>
<ul>
<li>市销率（P/S）比率：当前的市销率为 0.46，低于行业标准，暗示潜在的低估，并为考虑销售表现的投资者提供了投资机会。</li>
</ul>
<ul>
<li>企业价值与息税折旧摊销前利润（EV/EBITDA）分析：该公司的 EV/EBITDA 比率为 18.46，低于行业平均水平，表明可能被低估，这对注重价值的投资者可能是有利的。</li>
</ul>
<p><strong>市值分析：</strong> 该公司的市值低于行业平均水平，表明其相对于同行较小。这可能由于多种因素，包括被认为的增长潜力或运营规模。</p>
<h3>内部交易的相关性</h3>
<p>内部交易不应主要用于投资决策，但内部交易可以是投资决策中的一个重要因素。</p>
<p>在法律框架内，“内部人” 被定义为根据 1934 年证券交易法第 12 条，任何持有公司股权证券超过 10% 的官员、董事或实益所有者。这包括高管和主要对冲基金。这些内部人必须通过 Form 4 文件披露他们的交易，并在交易后的两个工作日内提交。</p>
<p>公司内部人发起的新购买行为是他们预期股票会上涨的强烈迹象。</p>
<p>然而，内部出售并不总是表明看跌的观点，可能受到多种因素的影响。</p>
<h3>关注的交易代码</h3>
<p>在交易方面，投资者 往往关注公开市场的交易，这在 Form 4 文件的表 I 中详细列出。Box 3 中的 <strong>P</strong> 表示购买，而 <strong>S</strong> 表示出售。交易代码 <strong>C</strong> 表示期权的转换，交易代码 <strong>A</strong> 表示从公司获得的证券的授予、奖励或其他获取。</p>
<p>查看 Astrana Health 内部交易的完整列表。</p>
<p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>

ASTH

<p>根据最近的 SEC 文件，Astrana Health（NASDAQ:ASTH）的董事 David Schmidt 行使了 20,000 股的股票期权，行使价格为 5.79 美元，价值 431,800 美元。Astrana Health 的股票目前价格为 27.38 美元。该公司报告了过去三个月 99.71% 的收入增长，但毛利率较低，仅为 10.17%，每股收益为 0.01。其市盈率为 144.11，表明可能存在高估，而市销率为 0.46 则暗示可能被低估。内部交易可能会影响投资决策，但不应作为唯一因素</p>

<p>Disclosed in a recent SEC filing on January 15, Schmidt, Director at <strong>Astrana Health</strong> (NASDAQ: ASTH), made a noteworthy transaction involving the exercise of company stock options.</p>
<div class="lb-trans"><p>在 1 月 15 日最近的 SEC 文件中，<strong>Astrana Health</strong>（纳斯达克： ASTH）的董事施密特进行了值得注意的交易，涉及行使公司股票期权。</p>
</div><p><strong>What Happened:</strong> A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Schmidt, Director at Astrana Health, a company in the Health Care sector, just exercised stock options worth 20,000 shares of ASTH stock with an exercise price of $5.79.</p>
<div class="lb-trans"><p><strong>发生了什么：</strong> 周四，美国证券交易委员会的 Form 4 文件显示，<strong>Astrana Health</strong> 的董事施密特刚刚行使了价值 20,000 股 ASTH 股票的股票期权，行使价格为 5.79 美元。</p>
</div><p>During Friday's morning session, <strong>Astrana Health</strong> shares down by 0.0%, currently priced at $27.38. Considering the current price, Schmidt's 20,000 shares have a total value of $431,800.</p>
<div class="lb-trans"><p>在周五的早盘交易中，<strong>Astrana Health</strong> 的股价下跌了 0.0%，目前价格为 27.38 美元。考虑到当前价格，施密特的 20,000 股总价值为 431,800 美元。</p>
</div><h3>Unveiling the Story Behind Astrana Health</h3>
<div class="lb-trans"><h3>揭示 Astrana Health 背后的故事</h3>
</div><p>Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.</p>
<div class="lb-trans"><p>Astrana Health Inc 是一家以患者为中心、以医生为中心的综合性人口健康管理公司。该公司致力于以成本效益的方式提供协调的、基于结果的医疗服务。它专注于医生提供高质量的医疗服务、人口健康管理和患者护理协调，特别是针对老年患者和多种慢性病患者。公司的三个可报告部门是护理合作伙伴、护理交付和护理赋能。它的主要收入来自护理合作伙伴部门。</p>
</div><h3>Key Indicators: Astrana Health's Financial Health</h3>
<div class="lb-trans"><h3>关键指标：Astrana Health 的财务健康状况</h3>
</div><p><strong>Revenue Growth:</strong> Over the 3 months period, Astrana Health showcased positive performance, achieving a revenue growth rate of <strong>99.71%</strong> as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> 在过去的三个月中，Astrana Health 表现积极，截至 2025 年 9 月 30 日，收入增长率达到了 <strong>99.71%</strong>。这反映了公司顶线收入的显著增长。与竞争对手相比，该公司的增长率超过了医疗保健行业的平均水平。</p>
</div><p><strong>Key Insights into Profitability Metrics:</strong></p>
<div class="lb-trans"><p><strong>盈利能力指标的关键见解：</strong></p>
</div><ul>
<li>Gross Margin: The company issues a cost efficiency warning with a low gross margin of 10.17%, indicating potential difficulties in maintaining profitability compared to its peers.</li>
</ul>
<div class="lb-trans"><ul>
<li>毛利率：该公司发出成本效率警告，毛利率仅为 10.17%，表明与同行相比在维持盈利能力方面可能面临困难。</li>
</ul>
</div><ul>
<li>Earnings per Share (EPS): Astrana Health's EPS reflects a decline, falling below the industry average with a current EPS of 0.01.</li>
</ul>
<div class="lb-trans"><ul>
<li>每股收益（EPS）：Astrana Health 的每股收益反映出下降，当前 EPS 为 0.01，低于行业平均水平。</li>
</ul>
</div><p><strong>Debt Management:</strong> Astrana Health's debt-to-equity ratio is below the industry average at <strong>1.4</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Astrana Health 的债务与股本比率为 <strong>1.4</strong>，低于行业平均水平，反映出对债务融资的依赖较低，财务策略更加保守。</p>
</div><p><strong>Assessing Valuation Metrics:</strong></p>
<div class="lb-trans"><p><strong>评估估值指标：</strong></p>
</div><ul>
<li>Price to Earnings (P/E) Ratio: Astrana Health's current Price to Earnings (P/E) ratio of 144.11 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.</li>
</ul>
<div class="lb-trans"><ul>
<li>市盈率（P/E）比率：Astrana Health 当前的市盈率为 144.11，高于行业平均水平，表明根据市场情绪，该股票可能被高估。</li>
</ul>
</div><ul>
<li>Price to Sales (P/S) Ratio: The current P/S ratio of 0.46 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>市销率（P/S）比率：当前的市销率为 0.46，低于行业标准，暗示潜在的低估，并为考虑销售表现的投资者提供了投资机会。</li>
</ul>
</div><ul>
<li>EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 18.46, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.</li>
</ul>
<div class="lb-trans"><ul>
<li>企业价值与息税折旧摊销前利润（EV/EBITDA）分析：该公司的 EV/EBITDA 比率为 18.46，低于行业平均水平，表明可能被低估，这对注重价值的投资者可能是有利的。</li>
</ul>
</div><p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 该公司的市值低于行业平均水平，表明其相对于同行较小。这可能由于多种因素，包括被认为的增长潜力或运营规模。</p>
</div><h3>The Relevance of Insider Transactions</h3>
<div class="lb-trans"><h3>内部交易的相关性</h3>
</div><p>Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision.</p>
<div class="lb-trans"><p>内部交易不应主要用于投资决策，但内部交易可以是投资决策中的一个重要因素。</p>
</div><p>Within the legal framework, an &#34;insider&#34; is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.</p>
<div class="lb-trans"><p>在法律框架内，“内部人” 被定义为根据 1934 年证券交易法第 12 条，任何持有公司股权证券超过 10% 的官员、董事或实益所有者。这包括高管和主要对冲基金。这些内部人必须通过 Form 4 文件披露他们的交易，并在交易后的两个工作日内提交。</p>
</div><p>The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.</p>
<div class="lb-trans"><p>公司内部人发起的新购买行为是他们预期股票会上涨的强烈迹象。</p>
</div><p>However, insider sells may not always signal a bearish view and can be influenced by various factors.</p>
<div class="lb-trans"><p>然而，内部出售并不总是表明看跌的观点，可能受到多种因素的影响。</p>
</div><h3>Transaction Codes To Focus On</h3>
<div class="lb-trans"><h3>关注的交易代码</h3>
</div><p>When it comes to transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A <strong>P</strong> in Box 3 denotes a purchase, while <strong>S</strong> indicates a sale. Transaction code <strong>C</strong> signals the conversion of an option, and transaction code <strong>A</strong> denotes a grant, award, or other acquisition of securities from the company.</p>
<div class="lb-trans"><p>在交易方面，投资者 往往关注公开市场的交易，这在 Form 4 文件的表 I 中详细列出。Box 3 中的 <strong>P</strong> 表示购买，而 <strong>S</strong> 表示出售。交易代码 <strong>C</strong> 表示期权的转换，交易代码 <strong>A</strong> 表示从公司获得的证券的授予、奖励或其他获取。</p>
</div><p>Check Out The Full List Of Astrana Health's Insider Trades.</p>
<div class="lb-trans"><p>查看 Astrana Health 内部交易的完整列表。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>
</div>

内部活动更新：David Schmidt 执行期权行权，在 Astrana Health 获得了 431,000 美元